Publication | Closed Access

Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells

Breast OncologyMedicinePharmacologyErbb Receptor PhosphorylationCell ViabilityBreast CancerImmune Checkpoint InhibitorAnti-cancer AgentCancer BiologyCell BiologyCell SignalingTumor Biology